BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Month: January 2025

12 posts

BioTech CEO InterviewsLan Su, COO of Lakeside Holding, Shares His Vision and Strategies for Charting New Horizons

  • BioTech Health X
  • January 27, 2025
Biotech Health X recently had the opportunity to sit down with Lan Su, the newly appointed Chief Operating…
0 Shares
0
0
0
0
0
0
0

Biotech NewsVoyager Therapeutics (VYGR) Reports $24.6M in Q3 2024 Collaboration Revenues

  • BioTech Health X
  • January 19, 2025
Voyager Therapeutics Inc. (VYGR) is a pioneering biotechnology company at the forefront of developing innovative gene therapies for…
0 Shares
0
0
0
0
0
0
0

Biotech NewsaTyr Pharma (ATYR) Raises $19.4 Million to Support Drug Development and Clinical Trials

  • BioTech Health X
  • January 19, 2025
aTyr Pharma Inc. (ATYR) is a pioneering clinical-stage biopharmaceutical company dedicated to developing novel, first-in-class therapies for patients…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAquestive Therapeutics (AQST) Reports Strong Q3 2024 Financial Results with 4% Revenue Growth

  • BioTech Health X
  • January 19, 2025
Aquestive Therapeutics Inc. (AQST) is a cutting-edge pharmaceutical company dedicated to transforming the way medicines are delivered to…
0 Shares
0
0
0
0
0
0
0

Biotech NewsThe Next Big Player in Immuno-Oncology: iTeos Therapeutics (ITOS)

  • BioTech Health X
  • January 19, 2025
iTeos Therapeutics Inc. (ITOS), a clinical-stage biopharmaceutical company, is dedicated to pioneering the discovery and development of next-generation…
0 Shares
0
0
0
0
0
0
0

Biotech NewsProtagonist Therapeutics (PTGX)Exceeds Revenue Estimates in Q3 2024

  • BioTech Health X
  • January 16, 2025
Protagonist Therapeutics Inc. (PTGX) is an innovative clinical-stage biopharmaceutical company that specializes in the discovery and development of…
0 Shares
0
0
0
0
0
0
0

Biotech NewsMadrigal Pharmaceuticals (MDGL): A Financial Powerhouse With $1.0 Billion Cash Position in 2024

  • BioTech Health X
  • January 16, 2025
Madrigal Pharmaceuticals Inc. (MDGL) is a pioneering biopharmaceutical company focused on developing and commercializing novel, life-changing therapies for…
0 Shares
0
0
0
0
0
0
0

Biotech NewsKamada (KMDA) Reports Strong Q3 2024 Financial Results with $41.7M in Revenue

  • BioTech Health X
  • January 14, 2025
Kamada Ltd. (KMDA) is a prominent global biopharmaceutical company that has established itself as a leader in the…
0 Shares
0
0
0
0
0
0
0

Biotech NewsGossamer Bio (GOSS) Reports Strong Q3 2024 Financial Results

  • BioTech Health X
  • January 14, 2025
Gossamer Bio Inc. (GOSS) is a prominent clinical-stage biopharmaceutical company based in San Diego, California, committed to the…
0 Shares
0
0
0
0
0
0
0

Biotech NewsLakeside (LSH) Partners with Huiyu Pharmaceutical to Expand Global Oncology Drug Distribution

  • BioTech Health X
  • January 7, 2025
Lakeside Holding Limited (LSH) is a dynamic U.S.-based cross-border supply chain solution provider, strategically headquartered in Itasca, Illinois.…
0 Shares
0
0
0
0
0
0
0

Biotech NewsSanara MedTech (SMTI) Achieves Record $21.7M Revenue in Q3 2024

  • BioTech Health X
  • January 2, 2025
Sanara MedTech Inc. (SMTI), headquartered in Fort Worth, Texas, is a leading medical technology company dedicated to developing…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAldeyra (ALDX) Reports $15.1M Q3 2024 Loss Amid R&D Investments

  • BioTech Health X
  • January 2, 2025
Aldeyra Therapeutics Inc. (ALDX) is a clinical-stage biotechnology company that stands at the forefront of innovation in addressing…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
  • Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
  • Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
  • Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
  • The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • February 13, 2026
    PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
    • February 13, 2026
    Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
    • February 13, 2026
    Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
    • February 13, 2026
    Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
    • February 13, 2026
    The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Posts
  • Verastem (VSTM) Isn’t “Small-Cap Roulette” Anymore—It’s a Commercial Oncology Ramp With a 2026 Twist
    • February 13, 2026
  • The Market Cap Is Small, the Idea Is Huge: Can Allogene (ALLO) Make CAR-T as Easy as Ordering a Drug?
    • February 13, 2026
  • 44% Real-World Response? Iovance (IOVA) Just Made “Off-the-Bench” Data the New Headline
    • February 13, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (787)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top